IDEAYA Biosciences Inc.

18.70-0.0900-0.48%Vol 118.63K1Y Perf 345.95%
Apr 15th, 2021 16:00 DELAYED
BID18.85 ASK20.36
Open18.78 Previous Close18.79
Pre-Market- After-Market-
 - -%  - -
Target Price
28.63 
Analyst Rating
Strong Buy 1.29
Potential %
53.10 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★+     54.68
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap603.26M 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
69.91 
Earnings Date
11th May 2021

Today's Price Range

18.5019.40

52W Range

4.2524.92

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
-5.84%
1 Month
-17.29%
3 Months
10.98%
6 Months
39.55%
1 Year
345.95%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
IDYA18.70-0.0900-0.48
AAPL134.502.47001.87
GOOG2 296.6641.82001.85
MSFT259.503.91001.53
XOM56.98-0.3400-0.59
WFC42.240.25000.60
JNJ160.390.47000.29
FB307.825.00001.65
GE13.55-0.1300-0.95
JPM152.170.96000.63
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.18-0.180.00
Q03 20201.34-0.17-112.69
Q02 20202.24-0.59-126.34
Q01 2020-0.57-0.59-3.51
Q04 2019-0.57-0.537.02
Q03 2019-0.67-0.5419.40
Q02 2019-0.63-1.30-106.35
----
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.24-84.62Negative
6/2021 QR-0.25-66.67Negative
12/2021 FY-0.975.83Positive
12/2022 FY-1.58-22.48Negative
Next Report Date11th May 2021
Estimated EPS Next Report-0.24
Estimates Count6
EPS Growth Next 5 Years %-
Volume Overview
Volume118.63K
Shares Outstanding32.26M
Trades Count2.49K
Dollar Volume1.77M
Avg. Volume213.20K
Avg. Weekly Volume164.37K
Avg. Monthly Volume218.09K
Avg. Quarterly Volume177.90K

IDEAYA Biosciences Inc. (NASDAQ: IDYA) stock closed at 18.7 per share at the end of the most recent trading day (a -0.48% change compared to the prior day closing price) with a volume of 137.66K shares and market capitalization of 603.26M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 58 people. IDEAYA Biosciences Inc. CEO is Yujiro S. Hata.

The one-year performance of IDEAYA Biosciences Inc. stock is 345.95%, while year-to-date (YTD) performance is 33.57%. IDYA stock has a five-year performance of %. Its 52-week range is between 4.25 and 24.92, which gives IDYA stock a 52-week price range ratio of 69.91%

IDEAYA Biosciences Inc. currently has a PE ratio of -14.60, a price-to-book (PB) ratio of 3.54, a price-to-sale (PS) ratio of 29.32, a price to cashflow ratio of 9.70, a PEG ratio of 2.32, a ROA of -16.38%, a ROC of -25.95% and a ROE of -22.43%. The company’s profit margin is -%, its EBITDA margin is -446.40%, and its revenue ttm is $19.54 Million , which makes it $0.61 revenue per share.

Of the last four earnings reports from IDEAYA Biosciences Inc., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.24 for the next earnings report. IDEAYA Biosciences Inc.’s next earnings report date is 11th May 2021.

The consensus rating of Wall Street analysts for IDEAYA Biosciences Inc. is Strong Buy (1.29), with a target price of $28.63, which is +53.10% compared to the current price. The earnings rating for IDEAYA Biosciences Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

IDEAYA Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

IDEAYA Biosciences Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 16.27, ATR14 : 1.59, CCI20 : -129.72, Chaikin Money Flow : 0.05, MACD : 0.28, Money Flow Index : 40.82, ROC : -17.44, RSI : 59.04, STOCH (14,3) : 17.62, STOCH RSI : 0.29, UO : 34.10, Williams %R : -82.38), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of IDEAYA Biosciences Inc. in the last 12-months were: Jason Throne (Sold 8 368 shares of value $98 994 ), Mark Lackner (Option Excercise at a value of $63 205), Mark Lackner (Sold 12 469 shares of value $204 178 ), Michael Dillon (Option Excercise at a value of $68 003), Michael Dillon (Sold 5 000 shares of value $103 697 ), Paul Stone (Option Excercise at a value of $42 966), Paul Stone (Sold 9 300 shares of value $167 150 ), Yujiro S. Hata (Option Excercise at a value of $34 480)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (85.71 %)
6 (85.71 %)
5 (83.33 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (14.29 %)
1 (14.29 %)
1 (16.67 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.29
Strong Buy
1.29
Strong Buy
1.33

IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.

CEO: Yujiro S. Hata

Telephone: +1 650 443-6209

Address: 7000 Shoreline Court, South San Francisco 94080, CA, US

Number of employees: 58

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

54%46%

Bearish Bullish

54%46%

News

Stocktwits